Tourmaline Bio
TRML
TRML was delisted on the 27th of October, 2025.
101 hedge funds and large institutions have $464M invested in Tourmaline Bio in 2024 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 40 increasing their positions, 22 reducing their positions, and 13 closing their positions.
82% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 22
69% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 13
10% more funds holding
Funds holding: 92 → 101 (+9)
7.14% more ownership
Funds ownership: 82.03% → 89.17% (+7.1%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
14% less capital invested
Capital invested by funds: $541M → $464M (-$77.1M)
65% less call options, than puts
Call options by funds: $89K | Put options by funds: $251K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$15.1M |
| 2 |
State Street
Boston,
Massachusetts
|
+$9.78M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$5.27M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$4.47M |
| 5 |
Pictet Asset Management
Carouge,
Switzerland
|
+$4.35M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BOCH
Blue Owl Capital Holdings
New York
|
-$11.4M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$8.7M |
| 3 |
Jennison Associates
New York
|
-$7.71M |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$4.13M |
| 5 |
Millennium Management
New York
|
-$3.65M |
TRML Hedge Fund Activity: Q4 2024 in Review
101 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Tourmaline Bio (TRML) for Q4 2024, worth a combined $464M — down 14% from $541M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new TRML positions and 13 closed out — a net gain of 9 holders — while 40 added to existing stakes and 22 trimmed.
The largest buyer was Adage Capital Partners, opening a new position worth an estimated $15.1M. The largest seller was Blue Owl Capital Holdings, cutting an estimated $11.4M.
- 101 institutional investors held Tourmaline Bio (TRML) as of Q4 2024, up from 92 in Q3 2024.
- Funds reported $464M of Tourmaline Bio stock for Q4 2024, down 14% quarter-over-quarter.
- 22 funds opened new Tourmaline Bio positions in Q4 2024 and 13 closed out, a net change of +9 holders.
- The largest Tourmaline Bio buyer in Q4 2024 was Adage Capital Partners, an estimated $15.1M added.
- The largest Tourmaline Bio seller in Q4 2024 was Blue Owl Capital Holdings, an estimated $11.4M sold.
Based on aggregated 13F filings for Q4 2024.